![Fudan University](https://trials-media.s3.amazonaws.com/orgs/fudan-university.jpeg)
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic...
Metastatic Colorectal CancerThis is a prospective, multi-center, randomized study evaluating the efficacy and safety of fruquintinib combined with chemotherapy vs bevacizumab combined with chemotherapy as second-line treatment in patients with metastatic colorectal cancer. Patients will receive fruquintinib+ FOLFIRI or bevacizumab+FOLFIRI as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine or bevacizumab+ capecitabine as maintenance treatment. All patients will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal.
![Agenus Inc.](https://trials-media.s3.amazonaws.com/orgs/agenus-inc.jpeg)
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal CancerThis is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
![Lyell Immunopharma, Inc.](https://trials-media.s3.amazonaws.com/orgs/lyell-immunopharma-inc.jpeg)
A Study to Investigate LYL845 in Adults With Solid Tumors
MelanomaNon-small Cell Lung Cancer1 moreThis is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
![City of Hope Medical Center](https://trials-media.s3.amazonaws.com/orgs/city-of-hope-medical-center.jpeg)
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment...
Metastatic Colon AdenocarcinomaMetastatic Colorectal Adenocarcinoma5 moreThis phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as FOLFOX, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Balstilimab and botensilimab are in a class of medications called monoclonal antibodies. They bind to proteins, called PD-L1 and CTLA-4, which is found on some types of tumor cells. These PD-1 and CTLA-4 proteins are known to affect the body's defense mechanism to identify and fight against tumor cells. The combination of these drugs may lead to improved disease control and outcomes in patients with MSS metastatic colorectal cancer.
![Shanghai East Hospital](https://trials-media.s3.amazonaws.com/orgs/shanghai-east-hospital.jpeg)
Assessment of Autologous Blood Marker Localization in Laparoscopic Colorectal Cancer Surgery
Colorectal CancerLaparoscopic colorectal surgery has been proved to have similar oncological outcomes with open surgery. Due to the lack of tactile perception, surgeons may have misjudgments in laparoscopic colorectal surgery. Therefore, the accurate localization of a tumor before surgery is important, especially in the early stages of cancer. Recently, some retrospective studies reported the use of patients' autologous blood for preoperative colonic localization in colorectal cancer with successful detection by laparoscopy, but its benefits remain controversial. This study aimed to assess the accuracy and safety of autogenous blood marker localization in laparoscopic radical resection for colorectal cancer.
![Ismail Gögenur](https://trials-media.s3.amazonaws.com/orgs/ismail-gogenur.jpeg)
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Metastatic Colorectal CancerThe trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently with irreversible electroporation (IRE) followed by a PD-1 inhibitor (pembrolizumab).
![Sun Yat-sen University](https://trials-media.s3.amazonaws.com/orgs/sun-yat-sen-university.jpeg)
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study
Colorectal Cancer MetastaticThe overall 5-year survival rate for patients with colorectal liver metastases (CRLM) is still less than 20%. Surgery-based local treatment can achieve no evidence of disease (NED) in CRLM patients, but over 60% of patients experience recurrence even after achieving NED. Even with adjuvant therapy for the 6-month perioperative period after achieving NED, the recurrence rate remains high. Fruquintinib is a selective anti-angiogenic inhibitor that may help reduce tumor recurrence and prolong the time to recurrence and metastasis. The Chinese Society of Clinical Oncology (CSCO) guidelines have recommended fruquintinib as a third-line therapy for colorectal cancer. This study aims to evaluate the effectiveness and safety of fruquintinib as a maintenance therapy for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy.
![Fudan University](https://trials-media.s3.amazonaws.com/orgs/fudan-university.jpeg)
Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC
Colorectal CancerThe goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is: The conversion surgery rate of the therapy mentioned above. The ORR, R0 surgery rate, DCR, PFS, OS, and safety will be evaluated.
![Guang'anmen Hospital of China Academy of Chinese Medical Sciences](https://trials-media.s3.amazonaws.com/orgs/guanganmen-hospital-of-china-academy-of-chinese-medical-sciences.jpeg)
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer
Advanced Colorectal CarcinomaTo clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.
![Cancer Research UK](https://trials-media.s3.amazonaws.com/orgs/cancer-research-uk.jpeg)
HTL0039732 in Participants With Advanced Solid Tumours
NeoplasmsProstatic Neoplasms14 moreThe purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.